8-K: Tyra Biosciences Reports Full Year 2023 Results and Secures $200 Million in Private Placement

Tyra Biosciences announced its full year 2023 financial results, highlighted clinical advancements, and secured a $200 million private placement financing.

Summary

• Tyra Biosciences reported its financial results for the fourth quarter and full year ended December 31, 2023.
• The company's net loss for the fourth quarter of 2023 was $22.8 million, compared to a $12.9 million loss in the same period of 2022.
• Research and development expenses for the fourth quarter of 2023 were $20.7 million, up from $10.4 million in the same period of 2022.
• The full year 2023 net loss was $69.1 million, compared to a $55.3 million loss in 2022.
• Full year 2023 research and development expenses were $62.5 million, compared to $43.0 million in 2022.
• As of December 31, 2023, Tyra had $203.5 million in cash, cash equivalents, and marketable securities.
• In February 2024, Tyra completed a $200 million private placement financing, bringing their pro-forma cash position to approximately $403.5 million.
• The company expects this cash position to support operations through at least 2026.
• Tyra's lead program, TYRA-300, is advancing in Phase 1/2 studies for oncology and is on track for a Phase 2 IND submission for achondroplasia in the second half of 2024.
• The company also initiated a Phase 1 study for TYRA-200 and dosed the first patient.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The successful capital raise and clinical advancements are positive, but the increased losses and R&D expenses are concerning. The overall sentiment is cautiously optimistic.

Positives

• The company successfully raised $200 million in a private placement, significantly strengthening its financial position.
• TYRA-300 received Rare Pediatric Disease Designation from the FDA, which could lead to a Priority Review Voucher.
• The company has multiple clinical programs advancing, including SURF301 and SURF201.
• The company has a strong cash position that is expected to fund operations through at least 2026.
• TYRA-300 has also received Orphan Drug Designation for the treatment of achondroplasia from the FDA.

Negatives

• The company's net loss increased in both the fourth quarter and full year of 2023 compared to 2022.
• Research and development expenses have increased significantly year-over-year.

Risks

• The company is early in its development efforts, and the approach based on its SNP platform is novel and unproven.
• There are potential delays in the commencement, enrollment, and completion of preclinical studies and clinical trials.
• Results from preclinical studies or early clinical trials may not be predictive of future results.
• The company is dependent on third parties for manufacturing, research, and preclinical testing.
• There is a risk of unexpected adverse side effects or inadequate efficacy of product candidates.
• The company may not realize the benefits associated with ODD or RPD designations.
• Unstable market and economic conditions may adversely affect the company's business and financial condition.

Future Outlook

Tyra expects its current cash position to support clinical and operational milestones through at least 2026. The company plans to submit an IND for a Phase 2 study in pediatric achondroplasia in the second half of 2024 and anticipates presenting initial results from the SURF301 Phase 1 study at a scientific congress in the second half of 2024.

Management Comments

• Todd Harris, CEO of TYRA, stated that 2023 was an outstanding year for TYRA and they have positive momentum at the start of 2024.
• Todd Harris believes TYRA-300 has the potential to become a best-in-class agent for multiple high-value indications.
• Alan Fuhrman, Chief Financial Officer of TYRA, noted that the company is in its strongest financial position to date, with a pro-forma cash position of over $400 million.
• Alan Fuhrman also stated that their ability to retain and attract high quality investors reflects the excitement around their pipeline.

Industry Context

Tyra Biosciences is operating in the competitive biotechnology sector, focusing on precision medicines targeting FGFR biology. The company's progress in clinical trials and its recent financing round position it to compete with other companies developing therapies in targeted oncology and genetically defined conditions. The focus on FGFR inhibitors is a growing area of interest in the industry.

Comparison to Industry Standards

• Tyra's increased R&D spending is typical for a clinical-stage biotech company advancing multiple programs.
• The $200 million PIPE financing is a significant capital raise, comparable to other biotech companies at a similar stage.
• The focus on FGFR inhibitors aligns with a growing trend in targeted oncology, with companies like Incyte and BridgeBio also developing therapies in this space.
• The company's cash runway through 2026 is a positive sign, as many biotech companies face funding challenges.
• The Rare Pediatric Disease Designation for TYRA-300 is a valuable asset, similar to other companies that have received such designations for their therapies.

Stakeholder Impact

• Shareholders will benefit from the strengthened financial position and the advancement of clinical programs.
• Patients with FGFR-related cancers and achondroplasia may benefit from the development of new therapies.
• Employees will have job security due to the company's strong financial position.
• The company's suppliers and partners will benefit from the continued operations and growth of the company.

Next Steps

• Tyra plans to submit an Investigational New Drug (IND) application to the FDA in the second half of 2024 for the initiation of the Phase 2 study for TYRA-300 in achondroplasia.
• The company expects to present initial results from its SURF301 Phase 1 portion at a scientific congress in the second half of 2024.
• Tyra will continue to advance its in-house precision medicine discovery engine, SNP.

Key Dates

Keywords

TYRA-300, TYRA-200, FGFR, Oncology, Achondroplasia, Clinical Trials, Private Placement, Rare Pediatric Disease Designation, Orphan Drug Designation, Biotechnology